Welcome to our dedicated page for Chemomab Therapeutics SEC filings (Ticker: CMMB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Chemomab Therapeutics Ltd. filings document a foreign private issuer focused on clinical-stage biotechnology and traded through American Depositary Shares. Its Form 6-K reports furnish operating updates, quarterly and year-end financial results, unaudited consolidated financial statements, management discussion and analysis, and press releases on the nebokitug program in primary sclerosing cholangitis.
The filing record also covers ADS and capital-structure matters, including at-the-market offering arrangements, ADS ratio-adjustment disclosures, shelf registration and equity incentive registration references, and annual general meeting materials. Proxy-related filings describe shareholder voting procedures for ADS holders, director elections, compensation policy approval, authorized share capital amendments, auditor re-appointment, quorum matters, and governance under Israeli company law.
Chemomab Therapeutics Ltd. director Gwen A. Melincoff reported an initial option holding in American Depositary Shares. She holds a stock option covering 8,621 underlying ADS with an exercise price of $1.86 per share, granted on June 1, 2026.
The option vests and becomes exercisable in equal monthly installments over a 36‑month period starting on June 1, 2026, and expires on June 1, 2036. This filing is an initial statement of beneficial ownership rather than a market purchase or sale.
Chemomab Therapeutics Ltd. announced several changes to its board and board committees. On June 1, 2026, the board appointed Gwen Melincoff as an independent Class I director and chair of the nominating and governance committee, bringing the board size to five directors.
On May 29, 2026, directors Claude Nicaise and Jill Quigley resigned from the board and the audit committee, with the company stating their resignations were not due to any disagreements over operations, policies, or practices. The board then appointed Neil Cohen and Nissim Darvish to the audit committee, with Cohen as chair, and reorganized the nominating and governance committee to be chaired by Melincoff with Darvish as a member.
Chemomab Therapeutics Ltd. Chief Executive Officer Mor George Adi reported buying American Depositary Shares on the open market. On May 29, 2026, he purchased 4,926 ADS at $2.08 and 4,878 ADS at $2.05, for a total of 9,804 ADS. Additional J-coded entries reflect RSU positions that, according to the footnotes, involved no transaction and are included for informational purposes only, with vesting running in quarterly installments through October 1, 2028 and April 10, 2029.
Chemomab Therapeutics reported first quarter 2026 results and highlighted new clinical data for nebokitug in primary sclerosing cholangitis (PSC) and PSC with co-existing inflammatory bowel disease (IBD). Management is advancing multiple partnering options for nebokitug, which has Orphan Drug and Fast Track designations for PSC.
For the quarter ended March 31, 2026, operating expenses were $1.85 million, down from $3.49 million a year earlier, reflecting lower research and development and general and administrative spending. Net loss narrowed to $1.77 million from $3.32 million, with basic and diluted loss per ordinary share improving to $0.003 from $0.007.
Cash and cash equivalents plus short-term bank deposits totaled $8.04 million as of March 31, 2026, compared with $10.37 million as of December 31, 2025. Total assets were $11.81 million and shareholders’ equity was $10.70 million, with current liabilities of $1.11 million, underscoring a balance sheet with low debt levels.
Chemomab Therapeutics Ltd. reported the results of its annual general shareholders meeting, which was originally scheduled for April 28, 2026 and adjourned to May 5, 2026 in Israel.
Shareholders approved the re-election of Mr. Neil Cohen and Dr. Claude Nicaise as Class II directors, a compensation policy for office holders and directors, an increase in the company’s authorized share capital with a related amendment to its articles of association, and the re-appointment of Somekh Chaikin (a KPMG member firm) as independent registered public accounting firm for the fiscal year ended December 31, 2026.
Chemomab Therapeutics Ltd. has adjourned its Annual General Meeting of Shareholders due to a lack of quorum. The meeting, originally scheduled for April 28, 2026 in Ramat Gan, Israel, has been postponed to May 5, 2026 at the same time and location.
The agenda and proposed resolutions remain as set out in the proxy statement furnished on March 20, 2026, which continues to govern the matters to be voted on. This report is also incorporated by reference into Chemomab’s existing Form F-3 and Form S-8 registration statements.
Chemomab Therapeutics Ltd. director and Chief Executive Officer Mor George Adi filed an initial ownership report showing his holdings in American Depositary Shares (ADSs), stock options, and RSUs. This Form 3 does not reflect new buying or selling activity; it establishes his existing equity position.
He holds options over 32,925 ADSs at an exercise price of $5.94 expiring in 2028 and options over 109,718 ADSs at $5.16 expiring in 2033, both directly. Indirectly, his spouse holds options over 8,431 ADSs at $3.20 expiring in 2026. Direct ADS holdings include 79,268, 31,712 and 18,750 shares, with an additional 50,059 ADSs held indirectly by his spouse. Footnotes describe RSU grants with quarterly vesting schedules through 2028 and 2029, highlighting that a portion of his equity exposure will vest over time rather than all at once.
Chemomab Therapeutics Ltd. director Darvish Nissim filed an initial ownership report showing existing equity interests in the company. The filing lists several stock options over American Depositary Shares with different exercise prices and expiration dates, alongside a smaller direct holding of 300 American Depositary Shares.
Multiple option grants, including those from October 28, 2016, April 19, 2021, March 7, 2022, March 21, 2023, and June 1, 2024, are fully vested and exercisable. Another grant from June 14, 2023 vests in 36 monthly installments and is scheduled to be fully exercisable by June 14, 2026.
Chemomab Therapeutics Ltd. director Neil Harris Cohen filed a Form 3 disclosing his initial beneficial ownership in the company’s American Depositary Shares. He directly holds 35,304 American Depositary Shares as of the reporting date.
He also holds several stock options to buy additional American Depositary Shares at exercise prices ranging from $2.14 to $109.04 per share, with expirations between 2030 and 2036. Footnotes state these options were granted between July 16, 2020 and March 16, 2025 and are all fully vested and exercisable as of the report date, showing his existing equity-based compensation position rather than new market transactions.
Chemomab Therapeutics Ltd. director Alan Charles Moses filed an initial Form 3 showing his holdings of stock options over American Depositary Shares. The filing lists several option grants at exercise prices ranging from $2.14 to $109.04 per ADS. According to the notes, these options are fully vested and exercisable as of the report date.